What is Intellia Therapeutics's D&A?

Intellia Therapeutics (NTLA) reported D&A of $2.2M in Q1 2026.

How has Intellia Therapeutics's D&A changed year-over-year?

Intellia Therapeutics's D&A decreased by 11.8% year-over-year, from $2.5M to $2.2M.

What is the long-term trend for Intellia Therapeutics's D&A?

Over 4 years (2021 to 2025), Intellia Therapeutics's D&A has grown at a 9.1% compound annual growth rate (CAGR), from $6.89M to $9.78M.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Intellia Therapeutics NTLA D&A

D&A at other companies

Ionis PharmaceuticalsIONS

$3.3M+48.2%

ALN

Alnylam PharmaceuticalsALNY

$13.55M-5.9%

CRISPR TherapeuticsCRSP

$4.32M-8.8%

Beam TherapeuticsBEAM

$5.61M+1.4%

Iovance Biotherapeutics, Inc.IOVA

$2.82M+9.8%

Viridian Therapeutics, Inc.VRDN

$121K+3.4%

Other financials

Income statement

See full

Revenue$15.0M-9.5%

Operating income-$100.5M+16.8%

Net income-$96.2M+15.8%

EPS (diluted)-$0.81+26.4%

Balance sheet

See full

Cash & equivalents$134.7M+6.2%

Total debt$80.5M-32.5%

Total equity$620.9M-20.4%

Total assets$758.8M-23.1%

Cash flow

See full

Operating cash flow-$117.3M+21.2%

CapEx$79.0K-89.3%

Free cash flow-$117.4M+21.5%

Valuation

See full

Market cap$2.17B+106%

Profitability

See full

Operating margin-636.6%-202pp

Net margin-597%-194pp

FCF margin-550.2%-140pp

Returns & leverage

See full

Return on equity-56.3%-1.5pp

Debt / equity0.1×0.0×

Current ratio6.1×+1.2×

Where this comes from

Reported directly by Intellia Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: Intellia Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Intellia Therapeutics's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Intellia Therapeutics's D&A?: Intellia Therapeutics (NTLA) reported D&A of $2.2M in Q1 2026.
How has Intellia Therapeutics's D&A changed year-over-year?: Intellia Therapeutics's D&A decreased by 11.8% year-over-year, from $2.5M to $2.2M.
What is the long-term trend for Intellia Therapeutics's D&A?: Over 4 years (2021 to 2025), Intellia Therapeutics's D&A has grown at a 9.1% compound annual growth rate (CAGR), from $6.89M to $9.78M.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.